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Abstract
Background: Many tools used to analyze microarrays in different conditions have been described. However, the integration
of deregulated genes within coherent metabolic pathways is lacking. Currently no objective selection criterion based on
biological functions exists to determine a threshold demonstrating that a gene is indeed differentially expressed.
Methodology/Principal Findings: To improve transcriptomic analysis of microarrays, we propose a new statistical approach
that takes into account biological parameters. We present an iterative method to optimise the selection of differentially
expressed genes in two experimental conditions. The stringency level of gene selection was associated simultaneously with
the p-value of expression variation and the occurrence rate parameter associated with the percentage of donors whose
transcriptomic profile is similar. Our method intertwines stringency level settings, biological data and a knowledge database
to highlight molecular interactions using networks and pathways. Analysis performed during iterations helped us to select
the optimal threshold required for the most pertinent selection of differentially expressed genes.
Conclusions/Significance: We have applied this approach to the well documented mechanism of human macrophage
response to lipopolysaccharide stimulation. We thus verified that our method was able to determine with the highest
degree of accuracy the best threshold for selecting genes that are truly differentially expressed.
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Introduction
Microarray technology [1] has emerged in the last decade as
the favoured method for large-scale gene expression studies. The
technique can be used to simultaneously analyse the expression of
thousands of genes and requires relatively small amounts of
starting RNA material, therefore it provides a powerful tool for
the comprehensive analysis of tissue or cell biology in response to
a given stimulus such as; an infection [2,3], a disease such as
cancer [4–6], chemoresistance [7] or development, e.g. cell
differentiation [8]. This means that the relationships between
genes and their involvement in specific cellular functions can be
better characterized. However, owing to the large number of
genes and to the small number of samples, there are many
statistical problems associated with microarray data [9,10], which
makes the detection of differential gene expression a challenging
task. One of the main problems is the huge amount of data
generated by microarray technology. Consequently, algorithms
such as Ingenuity Pathway Analysis, LSGraph, Cognia Molecu-
lar, Metacore, or Bibliosphere were developed to analyse and
understand complex biological systems. However, distinguishing
genes that undergo expression variation (EV) among all the genes
analysed remains difficult. Consequently, the normalization of
gene expression data [11] and the development of methods to
identify genes undergoing expression variation (EV) would
represent an important step forward. A number of papers have
described methods for assessing selected dataset requirements in
microarray experiments using statistical criteria [12]. However, in
all cases, the selection of genes undergoing expression variation is
associated with a stringency parameter. Lee and Whitmore [13]
used an ANOVA model and provided power calculations for
various alternative models. Muller et al. [14] used a decision-
theoretic approach and a hierarchical Bayes model. Wei et al.
[15] examined the roles of technical and biological variability, in
determining a selected data set. Pawitan et al. [16] assumed that
genes are independent and have equal variance, and the paper
reports on false discovery rates and sensitivities. Sample size
calculations for a microarray experiment package (ssize.fdr
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pilot data is used to estimate the variance. It focused on test power
and Type 1 errors (false negatives).
Increasing the stringency levels leads to the selection of genes
displaying the largest expression differences and thus to an
increase in Type 1 error risk. However, the lowering of the
stringency levels of selection means genes with a lower level of
expression variation are also chosen. Unfortunately, it also leads to
an increase in the risk of Type 2 errors (false positives).
Consequently, choosing the appropriate stringency threshold is
of crucial importance.
In this paper we address these issues, and propose a new
methodology for the analysis of micro-array transcriptional data in
which the stringency analysis threshold is not only determined
using statistical approaches but also intertwined with biological
considerations to allow for a more specific and sensitive selection
of the differentially regulated genes.
In our work, we statistically link gene selection stringency to an
expression variation or its p-value. Thereafter, the occurrence rate
parameter is associated with the percentage of donors whose
transcriptomic profile is similar. Next, we associated gene selection
and occurrence rate in order to further refine gene selection.
Finally, knowledge of biological interactions, canonical pathways
and these differentially expressed genes are then intertwined to
obtain an accurate threshold.
In order to validate this new statistical approach, we applied this
methodology to a well-known cellular activation model, i.e. the
LPS activated human peripheral blood derived macrophages [18–
20]. For study purposes, Monocyte Derived Macrophages (MDM)
from 6 blood donors were stimulated, or not, using LPS. As the
macrophage response to LPS has been extensively studied (about
8700 articles and 300 reviews). This gave us the framework with
which we could monitor the evolution of different analysis
parameters in order to maximize those providing the most useful
information. We clearly observed that an analysis with an
occurrence rate of 100% gives the most significant results and
enables the detection of genes with low expression variation
differences. However, there is the inherent risk of missing
important genes involved in the macrophage response to LPS.
On the one hand, increasing the occurrence rate reduces the
number of genes selected, but increases the risk of missing relevant
genes (Type I error). On the other hand, decreasing occurrence
rate will, of course, increase the number of genes selected, but also
the risk of ‘‘noise’’ i.e. irrelevant genes that would pollute the
selected dataset (Type II error). This would result in the inclusion
of non-relevant genes for macrophage response to LPS. Our
analysis clearly showed that information in the dataset increased
until an occurrence rate of 4/6 whereas this information was
partially lost for occurrences,4/6 because of increased noise
within the data set.
We clearly demonstrated that, when compared to other existing
methods, our statistical approach selects differentially expressed
genes with the highest degree of accuracy. It does so by providing
the most sensitive and specific threshold for gene selection.
Results
Selection of intertwined EVs and occurrence thresholds
for the analysis of gene expression
In order to identify macrophage genes which expression varies
during LPS activation, total RNA was harvested from human
monocyte-derived macrophages of the 6 donors cultured with, or
without, LPS activation. EV normalisations were robust and
provided accurate EV values.
Stringency level setting as a key parameter for gene
selection monitoring. Microarray data were analysed using
the EV method in order to identify differentially regulated genes
on paired data from the same donor. Analysis of gene expression
variation was carried out using two different comparison
approaches. Using a standard approach we selected genes for
which the EV mean measurement for the 6 donors was associated
with a p value#0.01. We obtained an EV of 2.32, and were able to
identify 68 or 69 differentially expressed genes when using the
mean or the median, respectively.
In the second approach, we used a higher p-value (p#0.1
corresponding to a value of EV$1.28). In this case, analysis was
performed with a decreasing EV occurrence from N=6/6 to
N$3/6 (Table 1). The probability that a gene will be differentially
expressed is a function of individual probabilities. Therefore, if a
gene has an EV$1.28 in at least 4 out of the 6 individuals (EV
occurrence$4/6), its minimum p-value is 10
22. For genes with an
EV occurrence=6/6 a minimum p-value of 10
26 can be reached.
At this last occurrence rate, 114 genes were selected and the
number of selected genes increased to 189 (N$5/6), 300 (N$4/6),
and 461 (N$3/6) for lower EV occurrences (Table 1).
Intertwining threshold settings and EV occurrence
rates. IPA analyses were then carried out on the different sets
of selected genes to determine the most suitable EV occurrence
threshold for identifying the largest set of genes associated with
LPS activation. As expected, in the case of decreased statistical
stringency, the following parameters; the number of IPA mapped
genes, the number of network eligible genes, and the total number
Table 1. Evolution of common gene output according to EV occurence.
Stringency
Genes
output
Eligible
network
Common
genes
Common
genes %
Genes in Main
network
Specific genes
in main network
Genes % in
main network
Best score of
main network
=6/6 114 79 8 13.13 76 68 86.08 49
$5/6 189 131 18 13.74 125 107 81.68 45
$4/6 300 202 63 31.19 193 130 64.36 38
$3/6 461 258 49 18.99 246 197 76.36 43
Each possible EV occurrence stringency level was tested, i.e. from =6/6 down to $3/6. EV analysis provides ‘‘Gene output’’ in the second column. Using Ingenuity
Pathway Analysis software we obtained the following data. The ‘‘Eligible Network’’ column which gives the number of genes belonging to a network. The ‘‘Common
Genes’’ column represents the total number of genes which have been found in at least two different networks. The ‘‘Common gene %’’ column provides the
percentage of genes shared by different networks. The next column gives the total number of genes in the main network, from which it is possible to calculate the
number of specific genes (genes in the main network minus genes common to at least two networks). The second last column presents specific genes as the
percentage of all genes in the main network (column Gene % in main network). Finally, the table displays the ‘‘best score of the main network’’ for each stringency level.
doi:10.1371/journal.pone.0013518.t001
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occurrence (Table 1). Therefore, these parameters are not
appropriate when determining the appropriate EV occurrence
threshold. However other analysis parameters did show interesting
features. The number of genes common to the different identified
networks increased to a maximum of 63 for an EV occurrence$4/
6 and dropped to 49 for an EV occurrence$3/6. The ratio of
genes connecting networks according to the total number of genes
associated to networks was twice as high (31.19%) for an EV
occurrence$4/6 when compared the other occurrences tested.
This finding demonstrates the optimal structuration of genes
selected at the above threshold.
This structure forming effect is lost for lower EV occurrence
as newly added genes tend to fall into new networks unlinked to
the ones identified at higher EV occurrence. Indeed, the dis-
tribution of the genes from the best network (network 1) for an
EV occurrence=6/6 are mainly found (56.5%) in the first
network, which has an EV occurrence rate of $5/6 (Table 2).
Similarly, 70.8% of genes in the best network with an occ-
u r r e n c er a t eo f$5/6 are found in the first network with an
occurrence rate$4/6. However, the genes in the first net-
work with an occurrence rate$4/6 are not found in the first
network at an occurrence rate of $3/6, but are mainly found in
the fourth network.
Consequently, an occurrence rate of $4/6 gave us the most
comprehensive and relevant information on the differentially
expressed genes associated with the LPS activation. We observed
that the number of genes associated to the 10 best canonical
pathways (Figure 1) increases in most (7/10) of the IPA identified
pathways until an occurrence rate of 4/6, but drops at an
occurrence rate of 3/6. This observation strengthened our
conviction that the EV$4 occurrence threshold was the optimal
setting. Taken together, these data show that by decreasing EV
occurrence, the number of genes considered to undergo expression
variation can be increased for the analysis of macrophage
activation by LPS. If relevant, the newly selected genes structurize
and interconnect the networks to reach a maximum value for an
EV occurrence$4/6. At less stringent EV occurrence values ($3/
6), the stronger networks lose their structure, and their
organization is re-examined under the influence of less relevant
genes. Therefore, we chose the EV value$1.3 and the EV
occurrence rate$4/6. These parameters were used to select 300
genes, which have to be analysed.
Analysis of the macrophage response to LPS at an EV
occurrence$4/6
Most differentially expressed genes are grouped within a single
meta network (Figure 2). Using EV threshold$1.28 and EV
occurrence$4/6, three hundred genes having undergone signif-
icant expression variation were identified in our experiments. IPA
mapped 277 genes, of which 202 could be associated to 22
networks. Thirteen of these are main networks interconnected by
at least one common gene, and together form a meta network.
The remaining 9 networks are deemed to be independent. For
example, the major network #1 shares: a common gene product
with network 5, two gene products with network 6, and one with
networks 7, 10 and 13, respectively. The composition of each
network is given in Table 3, which are classified into major and
minor networks according to their score and to the number of
genes identified and linked to these networks. The first twelve
networks were identified as major networks with fairly high scores
ranging from 38 for the best of them to 21 for the 12th. These
identified networks are made up of gene products selected
according to their EV ratio; varying from 23/35 (66%) for the
first network to 15/35 (43%) for the 12th network. It is worth
noting that the 13th network shares at least one common gene
product with 7 of the major networks. Although it generated a low
score (Score=3), this network strongly overlaps with the other
networks and can be considered as a member of the meta network
presented in Figure 2. Consequently, the latter is deemed to be
made up 13 major networks.
The other secondary networks are comprised of few gene
products and cannot be directly associated to major networks,
which signifies that only 9 out of the total of 202 gene products
were not associated to major networks. In Figure 3, we present in
more detail, the most likely network (i.e. network 1). It contains 10
under-expressed genes, which products are coloured green, and 13
over-expressed genes, which products are coloured red. The others
molecules were not detected as variant in our experiment. This
principal network is centred on NF-kappaB, which is known to play
a central role in LPS activation. Figure 3 also shows that NF-
kappaB interacts and upregulates target genes as illustrated by
ICAM1.
At this level of analysis, the minor networks, which were at first
considered to be less pertinent, should be re-analysed. For
instance, network 21 structured around DPEP2 (dipeptidase 2)
interacts through leukotriene D4 with up to three gene products
Table 2. Percentages of genes shared between networks for consecutively paired stringency levels.
N$5/6
N=6/6 Network 1 Network 2 Network 3 Network 4 Network 5
Network 1 56.5% 43.5% 8.7% 4.3%
N$4/6
N$5/6 Network 1 Network 2 Network 3 Network 4 Network 5
Network 1 70.8% 42.0% 12.5% 8.3%
N$3/6
N$4/6 Network 1 Network 2 Network 3 Network 4 Network 5
Network 1 11.5% 15.4% 50.0% 3.8%
Best score are in bold case.
Best scores are in bold print. As long as the best scores are shared between paired Nu1 networks, the stringency level may be too high, and should therefore be lowered.
Once the best score is no longer shared between Nu1 networks, the stringency level is deemed too low. Therefore, the preceding stringency level should be selected.
doi:10.1371/journal.pone.0013518.t002
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CRTPA interacts through PSCD gene products with five main
networks (data not shown). The interconnection of network 20 and
21 with the main network 2 is given in Figure 4. Overall, among
the 202 eligible gene products from a knowledge database, 193
gene products were highly interconnected through 63 common
gene products. The above genes structure the previously
mentioned Meta network (Figure 2).
Genes and molecular pathways affected by LPS
stimulation. Among the 300 macrophage genes undergoing
expression variation upon LPS stimulation, the pathway analysis
knowledge database has revealed that 178 gene products could be
defined as ‘‘Top Bio Functions’’ thanks to their score (data not
shown). Most relevant functions were associated with cell
signalling (85 gene products; p=2.14610
247), cancer (62 gene
products; p=1.17610
240), cell death (65 gene products;
p=9.07610
239), cell growth and proliferation (53 gene
products; p=8.29610
230), immune response (35 gene products;
p=4.87610
229), inflammatory diseases (40 gene products; p=
1.51610
227) and immune diseases (30 gene products; p=
4.63610
225). These are strongly overlapping bio functions and a
number of differentially expressed genes were common to two or
more categories. Therefore, almost 60% of our selected genes were
closely linked to cellular responses and/or cellular activation
processes.
CD14 and NF-kappaB target genes such as IL 1-/3, IL8,
ICAM1, MCP1, or MCP3 were up regulated upon LPS
stimulation of macrophages. These regulated genes are displayed
in the canonical pathways (Figure 5), and results are consistent
with LPS macrophage activation. It is worth noting that no
expression variation was observed for the COX-2 or i-NOS2
genes involved in the generation of the oxidative burst. Another
interesting finding was that a number of genes undergoing
expression variation after LPS stimulation were involved in
cellular lipid metabolism (Figure 2B). These include: the PPARc
nuclear receptor, genes coding proteins involved in fatty acid and
cholesterol transport (FABP3, FABP5, SCARB1) or enzymes
involved in cholesterol or lipid metabolism (ACAT1). Accordingly,
LPS/IL-1 mediated inhibition of the retinoid X receptor (RXR)
function and liver X receptor (LXR)/RXR activation was found
to be the most significantly affected pathway after 48 hours of LPS
stimulation (Figure 1). Finally, and most surprisingly, six
metallothionein genes are up regulated and found among the
networks (MT2A in network (N) 3 and N9, MT1B in N19, MT1E
in N1 and 6, MT1F in N2, MT1G in N2, MT1X in N8). One
pseudogene (C20ORF127 metallothionein pseudogene 3) was also
up regulated.
Estimation of inter-individual variability
After having verified intra chip homogeneity we evaluated inter
individual variability of the transcriptomic response. For each
individual, the set of genes with EV$2.32 (p#0.01) were selected
and compared two at a time. Maximum gene overlapping between
donors ranges between 43.9% and 77.6% (data not shown). For
paired individuals, all differentially expressed genes shared an
average overlap of 54%. We can therefore estimate the variability
level between two donors to be 46%. From this value it was
impossible to discriminate between biological and technical
variability. Nevertheless, technical variability has been evaluated
in reproducibility studies [21] and estimated to average 19.5%.
For our experiment, we considered technical variability to be 20%.
This calculation left us with a 26% average variability rate due to
Figure 1. Comparative analysis of the most significant Canonical Pathways throughout the entire dataset, and across multiple
datasets. The first 10 canonical Pathways generating significant scores are displayed as a bar chart along the x-axis. The y-axis represents the IPA
score: the taller the bar, the better the score for the indicated pathway. For each canonical pathway, we have compared the progression of this EV
value for increasingly tolerant values by decreasing EV occurrence; =6/6: blue; $5/6: red; $4/6: green; $3/6: violet.
doi:10.1371/journal.pone.0013518.g001
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variability estimations we calculated the number of expected genes
according to an EV occurrence. According to our observations
300 genes are differentially regulated at an EV$4/6. Given an
average inter individual variability of 46%, we expect to obtain
162 differentially expressed genes at an EV occurrence$5/6 and
87 differentially expressed genes at an EV occurrence=6/6.
Discussion
In recent years, micro-array studies have been increasingly used
to analyse tissue or cell response to a given stimuli [3,22–25], and
provide a lot of data for analysis. However, improved integration
of this huge mass of data is needed to better understand the
biological processes for which slight modifications in gene
expression can have significant consequences. In addition, study
design and/or statistical types of analysis only allow the detection
of genes undergoing the most significant expression variations, and
can only be seen as semi-quantative methods [26] at best. Indeed,
these studies may miss important genes which undergo slight
expression variations or appear as such on the micro-arrays. To
overcome this problem we describe an approach that we have
named ‘‘Expression Variation Occurrence Analysis’’. We linked
this approach to biological parameters to improve their threshold
parameter so that settings could be optimized. We then applied
our approach to the LPS-activated macrophages model to
experimentally verify and validate our prediction on a well-known
activation pathway.
Figure 2. Interconnections between different networks. From our 195 differentially expressed genes, and the applied parameters (EV=1.28;
EV occurrence$4/6), the data base has identified 22 different networks. The first 13 networks are heavily inter-connected as shown by solid lines
between the networks. The integer beside each line indicates the number of genes that two networks have in common. Networks from 14 to 22 do
not share common genes.
doi:10.1371/journal.pone.0013518.g002
Microarray Analysis Settings
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ID Molecules in Network Score
Focus
Molecules Top Functions
1 ALDH7A1, Angiotensin II receptor type 1, CCL2,C D 3 ,CD28, CD52,F a b p ,FABP3,
FABP5,F i b r i n ,FUCA1, GDF15, GNA15, ICAM1, Ifn gamma, IKK, IL1, IL18, LTA4H,
Mmp,M M P 7 ,MT1E,N F k B ,PDPN,p e p t i d a s e ,PGDS, S100A4, SERPINA1, SGK,
SLC2A6,S o d ,SOD2, SPHK1,T C R ,TIMP1
38 23 Cancer, Cellular Movement,
Hematological System
Development and Function
2 ABCE1, ACAT1, ANPEP, Ap1, AQP9, CDC42EP5, F Actin, FOXC2, FPR1, Histone h3,
IFITM1, Ige, Insulin, LDL, LEP, Mapk, MCL1, MT1G, ND4, NMB, P38 MAPK, PBEF1,
Pkc(s), Pld, PPARG, RGS2, RPS6KA1, Rxr, S100A8, S100A9, SCARB1, SHMT2, SNCA,
UGP2, Vegf
38 23 Lipid Metabolism, Molecular
Transport, Small Molecule
Biochemistry
3 ADCY3, Adenylate Cyclase, Alcohol group acceptor phosphotransferase, Alkaline Phosphatase,
APBB1, ATF3, C13ORF15, Calmodulin, CCL7, CCNB1, Ccnb1-Cdc2, CCNB1IP1, CD9, CD163,
CDC2,C k 2 ,CKS1B, Cyclin B, CYP1B1,E 2 f ,FCGR2A, HIST2H4A, LAIR1, LILRB2, MT2A,
PBX3, PCSK1N, PILRA, Pka, PLC, PTPN6, RNA polymerase II, RRM2, STMN1, YBX1
36 22 Cellular Compromise, Cell
Death, Cellular Assembly
and Organization
4 A2M,A k t ,C a l p a i n ,CCL13, CD14, CSF1R, CSF2RA (includes EG:1438), EIF4EBP1, ERK1/2,
FGFR4, Hsp70, IER3, IL8, IL7R, ISG15,J n k ,MBP, NFKBIA, PAK1,P d g f ,P D G FB B ,P I 3 K ,P L C
gamma, PP2A, Rac, RBP1, STAT, STAT5a/b, Syk, Tgf beta, TGFBI, TLR2, TNFAIP3, TREM1,
VAV
29 19 Hematological Disease,
Organismal Injury and
Abnormalities, Inflammatory
Disease
5 APOC1,A R T S - 1 ,CCL18, CECR1,C E T P ,D N M T 3 A ,EBP, EFNA3,e t h a n o l ,G A B P B 2 ,G A P D H
(includes EG:14433), H2AFY, HNRPA2B1, IFI27, IFITM1, IFNG, IL15, IL32, IL18RAP, IL1R2,
IL1RAP, IL7R, INS1, ISGF3G, KCNJ5,K I R 2 D L 3 ,LGALS3BP, MNDA, NKX2-1, OAS3
(includes EG:4940), PLTP, PRC1, SOD2, TAZ,Y Y 1
27 18 Lipid Metabolism, Molecular
Transport, Small Molecule
Biochemistry
6 ANXA1, BPHL, CD19, CD74, EMP1, FSTL1, GAL, GH1, GPNMB, GRB2, HADH, IL6, IL1RAP,
ISGF3G, KIF22, LGMN, LY9, MICAL1, MT1E, MYC, NTS (includes EG:4922), PNPT1,
PPP1R15A (includes EG:23645), RNASE6, RRM2, SCARB1, SEMA4A, SHMT2, SNX10,
SOD2, TAF9, TAL1, TNFRSF10B, TTC3, UBE2C
25 17 Cellular Growth and
Proliferation, Metabolic
Disease, Immune
Response
7 ALDH1A1, Angiotensin II receptor type 1, BTG1, CCL20, CD38, CMTM3, DCN, DHRS9,
EDNRA, ELAVL2, HOXA5, HOXA9, HOXB9, HS3ST1, HS3ST2, IER2, IGFBP7, IMPDH2,
KRT5, KRT14 (includes EG:3861), MAPK1, MAPK12, PNRC1, PRMT1, retinoic acid, RPL7,
S100A8, SERINC2, SERPINB9, SLA, SLC5A3, SOX4, sulfotransferase, TSC22D3, ZFAND6
23 16 Cellular Growth and
Proliferation, Cancer,
Cellular Development
8 ACP5, ALOX5AP, C5ORF13, CALCR, CCL7, CCL18, CD14, CDCA7L, CEBPE, CHST2,
CSN2, FCER2, FPR1, Hsp27, IL9, IL13, IL15RA, IL4I1, MAO, MAOA, Metalloprotease,
MT1X, PLCXD1, PPA1, PTGER2, PTGER4, PTGS2, QSOX1, SAMSN1, TM7SF4,
TNFRSF11A, TNFRSF11B, TNFRSF1B, TNFSF11, Ubiquitin
23 16 Embryonic Development,
Tissue Development,
Tissue Morphology
9 BDKRB1, C1q, C1QA, C1QB,C 1 R ,CHST2,C I D E C ,CKS1B,C R 1 ,EEF1B2, ERBB2, FDFT1,
ISG15,I T M 2 B ,KIFC3,L C N 2 ,LGALS3BP,M H CC l a s sI I ,MT2A,N I D 1 ,NINJ1, PABPC4,
PGM1, PTEN, RAB34, SEC61A1, SNN, SOX4, TFAP2C, TNF, TNFRSF9, TPST1,T P T 1 ,U C K 1 ,W A P
23 16 Hepatic System Disease,
Liver Hepatomegaly, Cell
Signaling
10 ADAMDEC1, Angiotensin II receptor type 1, beta-estradiol, CKS1B, DDIT4, FMO5,
GABRB2, GCHFR, GM2A, GRINA, HIST2H2AA3, HIST2H2BE, hydrogen peroxide, IFI6,
IFNB1, ISG15, LCN2, LILRA2, MAOA, MPZ, MSGN1, NPY1R, PDZK1IP1, PIGR, PMP22,
PNRC1, POMC, PPBP, progesterone, PTGER2, PTGER4, SLC3A2, SLC7A11, TBX19, TRAK2
21 15 Neurological Disease, Cellular
Growth and Proliferation,
Amino Acid Metabolism
11 ACE, BBC3, CASP3, Caspase, CSNK1D, CTSD, EIF4B, FLJ11259, GLIPR1, HIST1H2AD,
HMGB1 (includes EG:25459), HNRPU, HOXC6, IER3, IFITM2, IFITM3, IGFBP3, IKIP, IRF5,
ISGF3G, KIAA0101, MED21, NFYB, PER3, RRM2, SLC39A8, SMARCA4, SNCAIP
(includes EG:9627), TAF9, TBP, TFAM, TFB2M, TNNI2, TP53, UBE2D3
21 15 Cancer, Cell Death,
Gastrointestinal Disease
12 ALOX5AP, CD58, CDC42EP3, CEBPB, CNR2, cyclic AMP, FAAH, GATM, GCSH, glycine,
HLA-DPA1, HLA-DPB1, HP, IGHE, IL4, IL1B, IL1RAP, ISG15, LCN2, MARCO, Mhc2 Alpha,
NPW, ORM2, PIGR, PTGER4, S100A8, S100A9, SCGB3A1, SEMA4D, SLC2A9, SPRR1A
(includes EG:6698), TGTP, TMEM176A, TMEM176B, TREM2
21 15 Immune Response, Cellular
Movement, Hematological
System Development and
Function
13 adenosine, AHCY, AR, ATM, ATP, CASP3, E2F1, EIF2S3, FAIM, GZMB, HGF, hydrogen
p e r o x i d e ,I L 2 ,I L 4 ,I L 1 B ,J n k ,N A D +, NFkB, NFKB1, nitric oxide, NMNAT1, P2RX7, PARP1,
P C N A ,P R K C D ,P R K C E ,P R K D C ,r e t i n o i ca c i d ,SRGN,T N F ,T P 5 3 ,X R C C 5 ,X R C C 6 ,Y W H A Z ,Z I C 2
3 4 Cell Death, Hematological
Disease, Immunological
Disease
14 ACAD9, Acyl-CoA dehydrogenase 2 1 Amino Acid Metabolism,
Carbohydrate Metabolism,
Lipid Metabolism
15 NSD1, ZNF496 2 1 Developmental Disorder,
Genetic Disorder,
Embryonic Development
16 Malate dehydrogenase (oxaloacetate-decarboxylating) (NADP), ME3 2 1 Energy Production, Free
Radical Scavenging, Cellular
Function and Maintenance
17 Aldose 1-epimerase, GALM 2 1 Carbohydrate Metabolism
18 ARSK, Aryl Sulfatase 2 1 Lipid Metabolism
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we chose software, which is powerful enough to analyse the largest
number of genes within the same network. This was done to
illustrate the robustness of our analysis.
We have observed that by fine-tuning the stringency level
setting, some of the parameters simultaneously reached extremum
values, which indicated that optimum setting had been obtained.
Furthermore, at this threshold the transcriptional signal is highly
structured within a meta-network with a large number of genes
interconnecting major and minor networks. This structuring effect
is lost at lower EV occurrence thresholds, indicating that the genes
selected are not relevant to LPS macrophage activation, which
concurs with current knowledge. In our study only 3% of the 300
genes were estimated to be nonsignificant whereas in another
study using MPSS measurements more than 20% of 127 genes
were deemed to be nonsignificant [27].
The optimisation of the EV threshold/occurrence rate to
analyse the differentially regulated gene allowed us to confirm the
existence of a macrophage activation process mediated by the
TLR4/NF-kappaB pathway [28–30]. CD14, which interacts with
LBP to present LPS to TLR4 [31], was also found to be up
regulated [32] as well as a number of genes known to be NF-
kappaB targets or that have putative KB sites. Among those genes,
some promoted the inflammatory response (IL8 [33–34], MCP1
[35], MCP3 or ICAM1 [36]). Other genes such as NF-kappaBo r
SOD2 (encoding a free radical scavenging enzyme), played a key
role in reducing the extent the oxidative burst and hence cell
damage [37]. We were able to predict that some of the main up
regulation activity was not detected such as with NOS2 or COX2,
which encode for the main enzymes involved in reactive nitrogen
and oxygen species (RNS and ROS) production upon LPS
activation of macrophages. Because of late RNA extraction
(48 hours after LPS stimulation) we did not expect to see
differentially expressed gene that display an early and transient
response during the macrophage activation process [38]. Thus our
results are in agreement with those found for late extraction, in the
literature. A last significant finding was that an important subset of
identified regulated genes are involved in Lipid transport and
metabolism, which concurs with the fact that nuclear receptor
(LXR and RXRs) pathways were identified by automatic analysis
and that the peroxisome proliferator-activated receptor c (PPARc)
gene was found to be down regulated. PPARs and LXRs are
transcription factors activated by the products of lipid metabolism
[39], and are involved in regulating lipid metabolism and cellular
cholesterol homeostasis. Recent findings have also shown that they
play an important role as negative regulators (in association with
RXR receptors) of macrophage-mediated inflammation [40]
presumably through a mechanism of trans-repression directed
mainly at transcription factors such as NF-kappaB and AP-1 [41].
Analysis of differentially expressed genes with an appropriate EV
occurrence would appear to adequately reflect the macrophage
response to LPS activation and has highlighted the fact that
mechanism of macrophage inflammation regulation may be
triggered in the late phase of macrophage activation. This is
illustrated by evidencing overexpression of metallothionein (MT)
genes, which is known to be induced by inflammatory stress
[42,43]. In addition, MT genes carry specifically adapted
functions, which are tightly regulated through their expression as
discrete isoforms [44].
Interestingly a large proportion of genes involved in lipid
metabolism, such as PPRc, ACAT1, SCARB1 [45], FABP5 [46],
FOXC2 [47] were only found to be differentially expressed with a
more stringent EV occurrence rate and would not have been
detected by the approach where mean EV was calculated for all
the 6 donors. Other genes modulating the inflammatory response,
such as the MARCO scavenger receptor [48], IKKP (an inhibitor
of NFkBIA) or the macrophage inhibitory cytokine (MIC [49] or
GDF15) fall into the same category. This illustrates the sensitivity
and power of the EV occurrence analysis strategy when used to
describe cell transcriptomic response and to highlight the subtle
nature of regulation mechanisms. In addition to identifying genes
with low EV values and robust statistical evidences (p=10
26 for a
gene with EV$1.28 in all donors), EV occurrence analysis
provides an additional framework for the analysis of differentially
regulated genes. Genes commonly regulated in all donors can be
distinguished from those for which expression is associated with
inter-individual expression heterogeneity and only detected at
lower occurrence values. Genes found to be over or under
expressed in all individuals can be seen as important genes
involved in the response to the condition under study. This is
ID Molecules in Network Score
Focus
Molecules Top Functions
19 DIRAS3, MT1B 2 1 Cellular Development, Cancer,
Cellular Growth and
Proliferation
20 CRTAP, PSCD2, PSCD3 2 1 Cell Morphology, Cellular
Assembly and Organization,
Cell Signaling
21 DPEP, DPEP2, leukotriene D4 2 1 Cell Signaling, Immune
Response, Cellular Assembly
and Organization
22 SMS, Spermidine synthase, Spermine synthase 2 1 Amino Acid Metabolism,
Small Molecule Biochemistry,
Developmental Disorder
The genes found to be differentially regulated in our experiments and the number of such genes displayed in the ‘‘Focus molecules’’ column have been highlighted in
bold print. The score is generated using a p-value calculation and is displayed as the negative log of that p-value. This score indicates the likelihood that the assembly of
a set of focus genes in a network could be explained by random chance alone. A score of 2 indicates that there is a 1 in 100 chance that the focus genes are together in
a network due to random chance. Therefore, networks with scores of 2 or higher have at least a 99% confidence of not being generated by random chance alone. The
data base attributed general cellular functions to each network which are determined by interrogating the Ingenuity Pathway Knowledge base for relationships
between the genes in the network and the cellular functions they impact.
doi:10.1371/journal.pone.0013518.t003
Table 3. Cont.
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our study. Those evidenced at lower EV occurrences, as in the
case for a subset of lipid metabolism genes, may be genes with
minor expression differences and/or displaying differences in
expression behaviour between individuals. This is an important
point to consider in the context of the study of genetic
susceptibility to complex diseases. This is particularly true, as the
proposed workflow can be used to highlight differentially
expressed genes of interest that would not have been included in
a standard analysis because they exhibit inter-individual variability
for the same stimulus. Indeed, genes displaying inter-individual
expression heterogeneities may be seen as candidate genes that
highlight the genetic variability of individuals.
To conclude, we consider that EV occurrence analysis may be a
useful tool for analysing human cell behaviour in reaction to unknown
stimulus (such as cancer or pathogens). Differential gene expression can
thus be detected using robust statistical evidence, even for genes with
low expression differences, and the method described above provides
us with a more complete picture of the transcriptomic response.
Furthermore, it has the ability to identify inter-individual differences in
the cellular response that can be linked to disease susceptibility.
Materials and Methods
Cell Preparation and Culture Conditions
This study was conducted according to the principles expressed in
the Declaration of Helsinki. The study was approved by the
Institutional Review Board of l’Etablissement Franc ¸ais du Sang
Aquitaine Limousin (place Ame ´lie Raba Le ´on - 33000 Bordeaux -
FRANCE), and l’Universite ´ Victor Segalen - Bordeaux II (Labor-
atoire de Parasitologie, led by Professor Philippe VINCENDEAU;
146 rue Le ´o Saignat - 33000 Bordeaux - FRANCE, (ethics approval
re ´f. CPIS 10.11). All healthy volunteers provided written informed
consent for the collection of samples and subsequent analysis. Human
Figure 3. Close up of network. A maximum authorized number of 35 genes were used to generate a network. Direct interactions between each
gene within a network were represented. Genes highlighted in green were down-regulated whereas genes in red were up-regulated. The number
beside a gene name indicates its fold change expression. Genes in white, which were not found in the assay, were added by the data base as they are
relevant to the network. Solid lines represent a direct interaction whereas a dashed line represents an indirect interaction.
doi:10.1371/journal.pone.0013518.g003
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history of medical therapy in the previous two weeks. All samples
were processed together the same day. Briefly, the mononuclear cell
fraction was obtained by gradient centrifugation over Ficoll
(Histopaque 1077, Sigma-Aldrich Chimie, Lyon, France) and
monocytes were purified by CD14+ magnetic cell sorting (Miltenyi
Biotech) according to manufacturer’s instructions. Monocytes were
then seeded in 24-wellplates at 10
6cells per well (4 wellsper donor) in
complete Iscove’s Modified Dulbecco’s Medium (IMDM) supple-
mented with 10% heat-inactivated human type AB (Cambrex)
serum,ultra-glutamine2 mM,penicillin200 U/mlandstreptomycin
200 pg/ml. Cells were cultured for 5 days (with pre-warmed
complete medium change at day 3) to allow differentiation into
macrophages. At day 5, two wells per donor were stimulated with
100 ng/ml lipopolysaccharide (LPS, Escherichia coli,S i g m a )w h e r e a s
the two other wells were left as unstimulated controls (medium
change only). After 48 hours, all wells were washed with pre-warmed
phosphate-buffered saline (PBS). Total RNA was then extracted from
Figure 4. Connection of network 2 with minor networks. Networks are built as previously described in Figure 3. Genes that are in green were
down-regulated whereas genes in red were up-regulated. The number beside a gene name indicates its fold change expression. Genes in white,
which were not found in the assay, were added by the data base as they are relevant to the network. Solid lines represent direct interaction between
gene products whereas dashed lines represents indirect interaction. Orange lines display interconnections between minor networks (N 20 and N 21)
and major network 2.
doi:10.1371/journal.pone.0013518.g004
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includes a DNAse step, using the RNeasyH mini kit (Qiagen)
according to the manufacturer’s instructions. RNA quantity and
purity was quantified using a NanoDrop ND-1000 spectrophotom-
eter (Nanodrop Technologies) and assayed for degradation using an
Agilent bioanalyser (Agilent technologies, Santa Clara, USA)
according to the manufacturer’s instructions.
RNA labeling, hybridization and Microarray data
acquisition
One microgramme of each RNA was used to generate either
Cy3- or Cy5- RNA amplification (aRNA) target [50] using the
Amino Allyl Message Amp II aRNA amplification kit (Ambion,
Applied Biosystems, Courtaboeuf, France), according to manu-
facturer’s instructions. The macrophage transcriptional profile of
the 6 donors (being stimulated or not, by LPS) was evaluated
independently using the Operon Human Genome Array-Ready
Oligo Set
TM (AROS, Operon Technologies) Version 4.0, con-
taining 35,035 oligonucleotide probes representing approximately
25,100 unique genes and 39,600 transcripts. Prior to hybridiza-
tion, excess oligonucleotide was removed from the arrays by
shaking them twice for 1 min in 0.2% SDS. Arrays were then
washed twice in distilled water. The two labelled aRNA were
added to version 2 of microarray hybridization buffer (GE
Healthcare) in a final 50% formamide concentration, denaturated
Figure 5. Canonical pathway of differentially regulated genes after LPS stimulation mediated by the NF-kappaB pathway. Graphical
representation of the metabolic pathway LXR/RXR activation exhibited as the main metabolic pathway by the data base according to the best EV
value selection. The Toll-like receptor signalling pathway enables the production of cytokines with activation of NF-kappaB.
doi:10.1371/journal.pone.0013518.g005
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chambers of an automated slide processor (GE Healthcare).
Hybridization was carried out at 37uC for 12 hours. Hybridized
slides were washed at 37uC successively with 16SSC, 0.2% SDS
for 10 min, twice with 0.16SSC, 0.2% SDS for 10 min, with
0.16SSC for 1 min and with isopropanol before air drying.
Microarrays were immediately scanned at 10 mm resolution in
both Cy3 and Cy5 channels with a GenePix 4200AL scanner
(Molecular Devices) with a variable PMT voltage to obtain
maximal signal intensities with ,0.1% probe saturation. ArrayVi-
sion software (Alpha Innotech, Santa Clara, USA) was used for
feature extraction. Spots with high local background or contam-
ination fluorescence were flagged manually. A local background
was calculated for each spot as the median values of the
fluorescence intensities of 4 squares surrounding the spot. This
background was subtracted from the foreground of fluorescence
intensity. All data is MIAME compliant, the raw and normalized
data has been deposited in Gene Expression Omnibus (GEO)
database (GSE22858).
Measure of Expression variation and gene selection
Identification of differentially regulated genes was carried out
using the EV (Expression Variation) method [21], on paired data,
i.e. LPS stimulated macrophages versus unstimulated macrophag-
es from the same donor. This method can be used to analyze the
signal with regards to noise by normalizing and building
confidence bands of gene expression, and by fitting cubic spline
curves to the Box–Cox transformation. The confidence bands,
fitted to the actual variance of the data, include the genes devoid of
significant variation, and are used to calculate EV, based on the
confidence bandwidth. Each outlier is positioned according to the
dispersion space (DS) and provides a measure of gene EV
associated with a p-value. This model allows us to stabilize
variance.
Two approaches were then used to select genes for further
analysis. Firstly, genes with a mean of p-value#0.01 were
considered to be differentially regulated for different macrophages
culture conditions. Secondly, for each gene, we determined an EV
occurrence parameter corresponding to the number of time the
gene was found to vary in the same way among donors. In this
case we set a low statistical threshold for EV values with (p#0.1)
for inclusion of genes in the analysis.
As the transcriptomic chips Operon are embedded with
probes targeting the same gene, we compared the homogeneity of
EV values (EV$1.28 EV occurrence$4/6) of duplicated genes
present on the array. The mean, the median and standard
deviation of the replicates are equal to 7.35%, 6.15% and 5.88%
respectively, indicating that EV measurements are robust and
below 30% thus corresponding to an EV=1.28.
Pathway Analysis
The functional analysis algorithm developed by Ingenuity
Pathway Analysis (IPA) (IngenuityH Systems Inc., Redwoodcity
CA. USA, http://www.ingenuity.com) was used to identify the
networks, biological functions and/or diseases that were most
relevant to the dataset (i. e. the selected differentially expressed
genes). For this analysis, we selected the median value of
expression levels (calculated for the 6 individuals) as the
measurement of the level of expression considered for IPA. This
enables, in the case of the occurrence method, the minimization of
the extreme values effect and means that only the relevant
measurements calculated for the selected individuals are retained.
Network Generation. A dataset containing gene symbols
and the corresponding expression values was uploaded into the
application. Each gene identifier was mapped to its corresponding
gene object in the Ingenuity Pathways Knowledge Base. The genes
identified as significantly differentially regulated by IPA, called
focus genes, were overlaid onto a global molecular network
developed from information contained in the Ingenuity Pathways
Knowledge Base. Networks of these focus genes were then
algorithmically generated, based on their connectivity. A
network was limited to a maximum of 35 genes, which were
associated according to their functional connections. We
considered a network to be major if it was comprised of at least
20 differentially expressed genes. When necessary, some genes
were added to complete the network structure in accordance with
literature data.
Network Graphical Representation. A network is a
graphic representation of the molecular relationships between
genes or gene products. Genes or gene products are represented as
nodes, and the biological relationship between two nodes is
represented as an edge (line). All edges are supported by at least 1
reference from the literature, from a textbook, or from canonical
information stored in the Ingenuity Pathways Knowledge Base.
Human, mouse, and rat orthologs of a gene are stored as separate
objects in this base, but are represented as a single node in the
network. The intensity of the node colour indicates the degree of
up- (red) or down- (green) regulation. Nodes are displayed using
different shapes that represent the functional class of the gene
product. Edges are displayed with different labels that describe the
nature of the relationship between the nodes (e.g., P for
phosphorylation, T for transcription).
Functional Analysis of a Network. The Functional Analysis
of a network identifies the biological functions and/or diseases that
are most significant to the genes in the network. Fischer’s exact test
was used to calculate a p-value determining the probability that
each biological function and/or disease assigned to that dataset is
due to chance alone. The network genes, associated with biological
functions and/or diseases in the Ingenuity Pathways Knowledge
Base, were considered for the analysis. Fischer’s exact test was used
to calculate a p-value which determined the probability that each
biological function and/or disease assigned to that network is due
to chance alone.
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